Replies to post #731788 on NorthWest Biotherapeutics Inc (NWBO)

[JFR161162]

NWBO (DCVAX L + D) and Oncovir (POLY ICLC) are very attractive assets for MRK 

[laser777]

Good question.
I needed BCG in 2019 for bladder cancer.
They cut my treatment from 6 infusions per cycle to 4. This was 5 years ago. Still ongoing, so it seems. If Merck is playing hardball with NWBO, as suggested by some here, they really could care less about their patients. Why it takes this long to increase production is beyond me. Way too much power for big pharma!

[attilathehunt]

How does a company the size of Merck get caught unable to meet demand for a product it enjoys having sole control over? It's a huge blunder from inept planning. It's a glaring invitation for would-be suppliers to take away market share. What am I missing?

Perhaps all that building Merck is doing that dstock refers to has to do with this.

[dstock07734]

ILT,

LP can find an alternative to Merck's BCG easily.

Here is the company from Germany that can supply BCG.
https://www.medac-group.com/focus-areas/urology

I suspect Merck must have BMS's PDUFA of SC Opdivo in their mind.

Bristol Myers Squibb Announces Updated Action Date by the U.S. Food and Drug Administration for Subcutaneous Nivolumab (nivolumab and hyaluronidase)
Updated Prescription Drug User Fee Act (PDUFA) goal date of December 29, 2024

https://news.bms.com/news/details/2024/Bristol-Myers-Squibb-Announces-Updated-Action-Date-by-the-U.S.-Food-and-Drug-Administration-for-Subcutaneous-Nivolumab-nivolumab-and-hyaluronidase/default.aspx